摘要
Abstract
OBJECTIVE: To observe the clinical efficacy of Calcium dobesilate capsule combined with Niaoduqing granules in the treatment of IgA nephropathy. METHODS: 82 patients with IgA nephropathy were randomly divided into control group and treatment group. Control group was given Niaoduqing granules on the basis of conventional treatment, and treatment group was additionally given calcium dobesilate based on treatment of control group. After 3 months of treatment, therapeutic efficacies of 2 groups were observed. Changes of FIB, BUN, Scr, UA, Ccr and 24-h urine protein and adverse drug reactions in 2 groups were observed before and after treatment. RESULTS: After treatment, FIB level in treatment group was lower than before significantly, there was statistical significance (P＜0.05). Scr, UA and 24-h urine protein in 2 groups were decreased significantly (P＜0.05 or P＜0.01). Ccr in treatment group was significantly increased after treatment, there was statistical significance between 2 group (P＜0.05). No adverse drug reaction was found in control group, while 2 cases of mild adverse drug reaction were observed in control group. CONCLUSION : Calcium dobesilate combined with Niaoduqing granule is effective in the treatment of IgA nephropathy.关键词
羟苯磺酸钙胶囊/尿毒清颗粒/IgA肾病/临床疗效Key words
Calcium dobesilate capsule/ Niaoduqing granule/ IgA nephropathy/ Clinical efficacy分类
医药卫生
